Agentic Omics on 67AI Lab

Multi-Omics Integration: The Whole Is Greater Than the Sum

Sun, 26 Apr 2026 10:00:00 +0000

Introduction: Biology Does Not Happen One Modality at a Time

If genomics gives us the blueprint, transcriptomics shows what is being transcribed, proteomics shows what machinery is actually present, and metabolomics shows the biochemical consequences, then a single-omics analysis is always partial by construction. That is not a flaw in any one assay; it is a fact about biology. Cells regulate themselves through layered, noisy, nonlinear interactions. A DNA mutation may have no phenotypic consequence if the transcript is silenced. A dramatic RNA change may not matter if protein abundance is buffered. A protein-level perturbation may only become visible when a pathway rewires metabolism.

Decoding Gene Promoters: AI Cracks the Regulatory Grammar of Human DNA

Sun, 05 Apr 2026 13:00:00 +0000

Research Date: 2026-04-05
Category: AI-Genomics-Gene-Regulation
Focus: PARM deep learning model for predicting and designing promoter activity

The Bottom Line (TL;DR)

Scientists just built an AI that can read and write the “grammar” of gene promoters—the DNA switches that control when and where genes turn on. The model, called PARM (Promoter Activity Regulatory Model), can:

✅ Predict how active a promoter will be in different cell types—just from its DNA sequence
✅ Design custom promoters that work as well as natural ones
✅ Reveal the hidden “rules” of gene regulation that were mysterious for decades

Why it matters: This is a major step toward programmable gene expression—think precision gene therapies that activate only in the right cells, or regenerative medicine where we can control exactly which genes turn on during tissue repair.

The Road Ahead: Agentic Omics in 2027 and Beyond

Sun, 22 Mar 2026 00:00:00 +0000

Introduction: Standing at the Inflection Point

As we conclude the Agentic Omics series in March 2026, we find ourselves at a genuine inflection point. The past two years have witnessed extraordinary progress: AlphaFold 3’s extension to protein complexes and ligands, the emergence of 7B-parameter genome models like Evo, foundation models for single-cell biology achieving clinical utility, and the first wave of agentic systems orchestrating multi-step scientific workflows. Yet we also face sobering realities: Phase III clinical trial results remain the ultimate arbiter of success, regulatory frameworks are still crystallising, and the gap between computational prediction and biological causality remains stubbornly wide.

The Self-Driving Laboratory: Where Agents Meet Robots

Thu, 19 Mar 2026 10:00:00 +0000

Introduction: The Closed Loop of Discovery

For centuries, the scientific method has followed a familiar rhythm: a human scientist observes a phenomenon, formulates a hypothesis, designs an experiment, executes it manually or with basic automation, analyses the results, and iterates. This cycle — hypothesis, experiment, analysis, refinement — is the engine of scientific progress. But it’s also a bottleneck. Each iteration takes days, weeks, or months. Human bandwidth limits the search space we can explore. And crucially, the loop is open: the scientist must close it manually, bringing their intuition and experience to bear at every step.

Biosecurity and Dual-Use Risks of Biological AI

Wed, 18 Mar 2026 10:00:00 +0000

The Dual-Use Dilemma

In July 2024, the Arc Institute published a paper in Science describing Evo, a 7.6 billion parameter foundation model trained on 300 billion nucleotides spanning all domains of life. The model could generate functional DNA sequences, predict fitness effects of mutations, and even design novel regulatory elements. It was a scientific breakthrough—and immediately raised a question that every researcher in biological AI now confronts: Could this same technology be used to create biological weapons?

Open Source vs. Closed: The Battle for Biological AI

Tue, 17 Mar 2026 10:00:00 +0000

Introduction: The Open Science Paradox

In May 2024, Google DeepMind published AlphaFold 3 in Nature, describing a system that could predict the structure of protein complexes with DNA, RNA, ligands, and small molecules—a dramatic leap beyond AlphaFold 2’s protein-only predictions. But there was a catch: the code wasn’t released. For six months, researchers could read about the breakthrough but couldn’t reproduce it, build on it, or verify the claims independently.

Ethics, Bias, and Equity in Omics AI

Mon, 16 Mar 2026 10:00:00 +0000

Introduction: The Promise and the Peril

Precision medicine promised to treat each patient as an individual — to move beyond one-size-fits-all therapies to interventions tailored to your unique biology. AI-driven omics seemed poised to accelerate this vision: algorithms that could read your genome, interpret your proteome, and predict your disease risk with unprecedented accuracy.

But there’s a problem. The data powering these algorithms is profoundly unrepresentative of human diversity.

As of 2024, over 94% of participants in genome-wide association studies (GWAS) are of European ancestry, despite Europeans comprising only about 16% of the global population. This imbalance isn’t just a statistical curiosity — it has real consequences. Polygenic risk scores trained on European data perform significantly worse for individuals of African, Asian, Hispanic, and Indigenous ancestry. Variant classification algorithms misclassify pathogenic mutations in underrepresented populations. And the AI tools now entering clinical practice risk cementing these disparities into healthcare systems worldwide.

Clinical Translation: From Omics AI to Patient Outcomes

Sun, 15 Mar 2026 10:00:00 +0000

The Ultimate Test: Does It Help Patients?

After eighteen posts exploring the technical landscape of agentic omics—from foundation models for DNA and proteins to multi-agent systems for drug discovery—we arrive at the question that matters most: does any of this actually improve patient outcomes?

The answer is more nuanced than the hype suggests. As of early 2026, the FDA has approved over 1,000 AI/ML-enabled medical devices, but only a small fraction operate on genomic or pathology data with demonstrated clinical utility (IntuitionLabs, 2025; Nature Digital Medicine, 2025). The gap between a model that achieves 95% accuracy on a benchmark and a tool that measurably extends survival remains wide—and crossing it requires navigating regulatory pathways, clinical validation studies, and the messy reality of healthcare IT infrastructure.

Multi-Agent Systems for Biology: Collaborative AI Teams

Sat, 14 Mar 2026 10:00:00 +0000

Introduction

No single AI agent can master all of biology. A genomics specialist doesn’t reason like a proteomics expert. A literature review agent has different skills from an experimental design agent. Yet biological discovery demands all of these perspectives working together.

This is the promise of multi-agent systems for biology: collaborative AI teams where specialized agents debate, coordinate, and peer-review each other’s work — mimicking the collaborative nature of real scientific teams.

Agents for Cancer Genomics: Toward Autonomous Precision Oncology

Fri, 13 Mar 2026 10:00:00 +0000

Introduction: The Precision Oncology Imperative

Cancer is not one disease but hundreds—each with distinct molecular drivers, treatment responses, and clinical trajectories. The promise of precision oncology is simple in concept but staggering in execution: match the right treatment to the right patient at the right time, guided by the molecular profile of their tumor.

In practice, this requires orchestrating a complex workflow: tumor sequencing to identify mutations, interpretation of those variants against clinical databases, integration of genomic data with transcriptomic and proteomic profiles, therapy matching against drug databases, clinical trial matching, and longitudinal monitoring for resistance and recurrence. Each step generates data, requires expert interpretation, and carries uncertainty.

Agents for Drug Discovery: From Target to Molecule

Thu, 12 Mar 2026 10:00:00 +0000

Agents for Drug Discovery: From Target to Molecule

The pharmaceutical industry faces a productivity crisis. Developing a new drug costs an average of $2.3 billion and takes 10-15 years, with over 90% of candidates failing in clinical trials. Traditional drug discovery is a sequential, labor-intensive process: identify a target, validate it, screen millions of compounds, optimize leads, test safety, run clinical trials. Each stage can take years.

Agentic AI — autonomous systems that reason, plan, and execute multi-step workflows — promises to compress this timeline dramatically. By orchestrating domain-specific models (AlphaFold for structure, ESM for protein embeddings, generative models for molecule design) with LLM reasoning, agents can automate the entire pipeline from target identification to clinical candidate selection.

Building Biological Tool-Use Agents: Architecture and Patterns

Wed, 11 Mar 2026 10:00:00 +0000

Building Biological Tool-Use Agents: Architecture and Patterns

The vision of agentic omics — autonomous AI systems that orchestrate biological discovery — depends on a deceptively simple capability: tool use. An agent that can reason about biology but cannot access BLAST, AlphaFold, or single-cell analysis pipelines is like a biologist who understands theory but has never touched a pipette.

This post provides a practical architecture for building biological tool-use agents. We cover the essential tool inventory, the unique error-handling challenges of biological data, prompt engineering patterns for biological reasoning, and a reference architecture based on the ReAct (Reason + Act) loop. This is the “how-to” companion to Post 13’s conceptual overview and Post 14’s vision of agentic omics.

The Agentic Omics Vision: LLMs Meet Domain-Specific AI

Tue, 10 Mar 2026 10:00:00 +0000

Introduction: The Convergence Point

In Post 13, we defined agentic AI as systems that autonomously plan, reason, use tools, and execute multi-step scientific workflows. Now we arrive at the central thesis of this entire series: Agentic Omics — the convergence of large language model (LLM) reasoning with domain-specific biological AI models like AlphaFold, ESM, scGPT, and DNABERT to create autonomous systems capable of end-to-end biological discovery.

This is not science fiction. As of early 2026, agentic systems are being deployed in operational drug discovery settings at companies like AstraZeneca, with documented implementations compressing workflows that once took months into hours while maintaining scientific traceability (Seal et al., 2025). The question is no longer if this convergence will transform biology, but how — and what architecture will get us there most reliably.

What Is Agentic AI? From Chatbots to Autonomous Scientific Agents

Sat, 07 Mar 2026 10:00:00 +0000

Introduction: Beyond the Chatbot

When you ask ChatGPT a question, it answers. When you ask an agentic AI system a question, it acts. This distinction — between passive assistance and autonomous execution — marks one of the most significant shifts in artificial intelligence since the transformer architecture itself.

Agentic AI systems are not merely more sophisticated chatbots. They are autonomous entities capable of perception, reasoning, planning, tool use, action, and memory. They can independently execute multi-step workflows, make decisions when faced with uncertainty, and adapt their approach based on feedback from the environment. In scientific contexts, this means agents that can read literature, formulate hypotheses, design experiments, execute computational analyses, interpret results, and iterate — all with varying degrees of human oversight.

Single-Cell Multi-Omics: The Cellular Resolution Revolution

Fri, 06 Mar 2026 19:38:00 +0000

Introduction: The Cellular Resolution Frontier

Biology has always been a story of scale. For decades, we studied organisms, then tissues, then cell populations — averaging signals across thousands or millions of cells. But tissues are not homogeneous. A tumor contains cancer cells, immune cells, fibroblasts, and endothelial cells, each with distinct molecular profiles. The brain contains hundreds of neuronal subtypes, each with unique functions. Even “identical” cells in culture exhibit stochastic variation in gene expression that can determine cell fate.

AI for Phenomics: When Images Meet Molecules

Thu, 05 Mar 2026 00:00:00 +0000

The Visible Layer of Biology

While genomics reads the book of life and proteomics predicts the machinery that executes it, phenomics observes the actual outcome—the visible traits, cellular morphologies, and clinical presentations that emerge from the interplay of genes, environment, and chance. It is the layer we can see, measure, and often directly connect to disease.

Yet phenomics has historically been the poor cousin of molecular omics. High-throughput sequencing transformed genomics and transcriptomics into data-rich disciplines, while phenotyping remained labor-intensive, subjective, and low-throughput. A pathologist examining tissue slides. A physician recording clinical observations. A biologist peering through a microscope.

AI for Metagenomics: Decoding the Microbiome

Wed, 04 Mar 2026 08:00:00 +0000

AI for Metagenomics: Decoding the Microbiome

The human microbiome is often referred to as our “second genome.” Comprising trillions of microorganisms—bacteria, archaea, fungi, and viruses—these hidden ecosystems outnumber human cells and contain vastly more genetic diversity than our own DNA. But where human genomics deals with a single species and a relatively static genome, metagenomics is the study of a dynamic, highly complex, and constantly shifting multi-species community.

Decoding the microbiome is arguably one of the most data-rich and complex challenges in modern biology. Traditional bioinformatics tools, while foundational, have struggled with the compositionality, sparsity, and high dimensionality of metagenomic data.

AI for Metabolomics: The Chemical Fingerprint of Life

Tue, 03 Mar 2026 08:00:00 +0000

Welcome back to Agentic Omics: When AI Reads the Book of Life. In our previous installments, we explored how foundation models and artificial intelligence are revolutionizing genomics, transcriptomics, and proteomics. We’ve seen how DNA, RNA, and proteins can be treated as languages, allowing transformer architectures to parse their meaning with unprecedented accuracy.

Today, we turn to a different beast: Metabolomics.

Metabolomics—the large-scale study of small molecules, or metabolites, within cells, biofluids, tissues, or organisms—represents the chemical phenotype of biological systems. Unlike DNA or proteins, which are linear polymers built from defined alphabets (4 nucleotides, 20 amino acids), metabolites are incredibly diverse structural entities. They do not form a neat sequence. They are the downstream products of gene expression and protein activity, intimately influenced by diet, environment, and microbiome. They are the chemical fingerprint of life at a given moment.

AI for Proteomics: From AlphaFold to Protein Design

Mon, 02 Mar 2026 08:00:00 +0000

Protein artificial intelligence is, without question, the most mature and publicly celebrated discipline within the “omics” family. When we discuss AI in biology, the conversation inevitably drifts toward the 2024 Nobel Prize in Chemistry—awarded jointly to David Baker for computational protein design, and to Demis Hassabis and John Jumper for protein structure prediction via AlphaFold.

However, structure prediction was merely the opening act. Today, the frontier has rapidly shifted from static structure prediction to protein design (creating entirely new proteins), function prediction, and complex interaction modeling. In this seventh installment of the Agentic Omics series, we will dissect the current state of AI in proteomics, evaluate the monumental shifts from AlphaFold 2 to AlphaFold 3 and ESM-3, explore generative models like ProGen and RFdiffusion, and critically assess their real-world clinical impact in drug discovery.

AI for Transcriptomics: Understanding Gene Expression at Scale

Sun, 01 Mar 2026 08:00:00 +0000

Introduction: The Language of the Cell

While genomics maps the static blueprint of life, transcriptomics captures its dynamic execution. If the genome is the dictionary, the transcriptome is the conversation—the precise subset of genes being expressed by a specific cell, at a specific moment, under specific conditions. For decades, bulk RNA sequencing averaged these conversations across millions of cells, giving us a cacophonous blend that masked individual cellular identities. The advent of single-cell RNA sequencing (scRNA-seq) changed everything, allowing us to listen to individual cellular voices.

AI for Genomics: Reading the Book of Life with Transformers

Sat, 28 Feb 2026 08:00:00 +0000

The genome is the ultimate source code. For decades, computational biologists have relied on alignment algorithms, hidden Markov models, and specialized machine learning to decode it. Today, a new paradigm is taking hold: DNA foundation models. By treating the genome as a vast, continuous text and training large language models (LLMs) on billions of nucleotides, researchers are teaching AI to “read” the book of life in its native language.

In this fifth installment of our Agentic Omics series, we examine the state of the art in genomic AI. We explore how models like DNABERT-2, Nucleotide Transformer, Evo, and HyenaDNA are moving beyond sequence classification to predict gene expression, identify regulatory elements, and quantify variant effects. Crucially, we will dissect the architectural innovations that make this possible—and the biological complexities that still confound these models.

Benchmarks and Evaluation: How Do We Know If Omics AI Actually Works?

Fri, 27 Feb 2026 08:00:00 +0000

When a new foundation model in computational biology is released, the accompanying paper inevitably features tables of bolded numbers demonstrating state-of-the-art performance. Whether it is predicting protein structures or annotating single-cell data, the claims are often spectacular. But how do we truly know if these AI systems work in ways that matter to biology, rather than just optimizing arbitrary computational metrics?

For the vision of Agentic Omics to become reality—where autonomous agents orchestrate models like AlphaFold and DNABERT-2 to drive drug discovery—we need a rigorous understanding of when these models succeed, when they hallucinate, and when their benchmarks deceive us. Claims of AI breakthroughs are only as strong as their evaluation methodologies.

The Data Infrastructure Challenge: From Raw Reads to AI-Ready Datasets

Fri, 27 Feb 2026 08:00:00 +0000

The bottleneck for AI in computational biology is rarely a shortage of sophisticated models; it is the sheer difficulty of making biological data AI-ready. The “Agentic Omics” vision—where autonomous AI agents orchestrate domain-specific models to accelerate drug discovery—fundamentally rests on the assumption that these agents have access to standardized, clean, and computable data.

In this post, we explore the unglamorous but critical foundation of omics AI: the data infrastructure. We trace the journey from raw sequencing reads to the structured tensor formats required by modern foundation models, exploring the evolving standards, the scale of the challenge, and how cloud infrastructure is adapting.

Foundation Models Meet Biology: The Transformer Revolution in Life Sciences

Wed, 25 Feb 2026 08:00:00 +0000

In the first post of this series, we mapped the omics landscape: genomics, transcriptomics, proteomics, metabolomics, metagenomics, phenomics. The next question is obvious: why did AI suddenly get so good at several of these fields at once?

The short answer is that biology turned out to be unusually compatible with the same family of models that transformed natural language processing. DNA, RNA, proteins, and even single-cell expression matrices are not “language” in any literal sense, but they are structured symbol systems with long-range dependencies, rich context, and vast quantities of unlabeled data. That is exactly the setting where self-supervised foundation models thrive.

The Omics Revolution: A Map of the Territory

Wed, 25 Feb 2026 08:00:00 +0000

Welcome to the first installment of Agentic Omics: When AI Reads the Book of Life. In this 24-part series, we will systematically review the state of the art of Artificial Intelligence (AI) across all major omics disciplines. We will explore how large language models, foundational transformer architectures, and eventually fully autonomous “Agentic Omics” systems are orchestrating domain-specific models to accelerate drug discovery, personalized medicine, and our fundamental understanding of biology.